Monoamine oxidase inhibition for tobacco pharmacotherapy

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 4, 2008, Pages 619-621

  George, T P ^a   Weinberger, A H ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING); BETA CARBOLINE; CLORGYLINE; ENSAM; HARMAN; LAZABEMIDE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NICOTINE; PARAGYLINE; PHENYLZINE; PLACEBO; RASAGILINE; SELEGILINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VARENICLINE;

CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG INHIBITION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; MORBIDITY; MORTALITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; TOBACCO DEPENDENCE; UNITED STATES;

CLINICAL TRIALS AS TOPIC; HUMANS; ISOENZYMES; MONOAMINE OXIDASE INHIBITORS; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 40949099176     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100474     Document Type: Review

References (25)

1. Giovino, G.A. Epidemiology of tobacco use in the United States. Oncogene 21, 7326-7340 (2002).
2. George, T.P. & O'Malley, S.S. Current pharmacological treatments for nicotine dependence. Trends Pharmacol. Sci. 25, 42-48 (2004).
3. Lewis, A., Miller, J.H. & Lea, R.A. Monoamine oxidase and tobacco dependence. Neurotoxicology 28, 182-195 (2007).
4. Berlin, I. et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin. Pharmacol. Ther. 58, 444-452 (1995).
5. Biberman, R., Neumann, R. & Gerber, Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 98, 1403-1407 (2003).
6. George, T.P., Vessicchio, J.C., Termine, A., Jatlow, P.I., Kosten, T.R. & O'Malley, S.S. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol. Psychiatry 53, 136-143 (2003).
7. Houtsmuller, E.J., Thornton, J.A., & Stitzer, M.L. Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology 163, 213-220 (2002).
8. Dani, J.A. & Harris, R.A. Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat. Neurosci. 8, 1465-1470 (2005).
9. McGehee, D.S., Iacoviello, M. & Mitchum, R. Cellular and synaptic effects of nicotine. In Medication Treatments for Nicotine Dependence (ed. George, T.P.) Ch. 2, 25-38 (Taylor and Francis, Boca Raton, FL, 2006).
10. Bodkin, J.A. & Amsterdam, J.D. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am. J. Psychiatry 159, 1869-1875 (2002).
11. Shih, J.C. & Chen, K. Regulation of MAO-A and MAO-B gene expression. Curr. Med. Chem. 11, 1995-2005 (2004).
12. Ito, H. et al. Monoamine oxidase polymorphisms and smoking behaviour in Japanese. Pharmacogenetics 13, 73-79 (2003).
13. Czerniczyniec, A., Bustamante, J. & Lores-Arnaiz, S. Modulation of brain mitochondrial function by deprenyl. Neurochem. Int. 48, 235-241 (2006).
14. Palfi, M., Szoko, E. & Kalman, M. Molecular mechanisms of the neuroprotective effect of (-)deprenyl. Orv. Hetil. 147, 1251-1257 (2006).
15. Berlin, I., Said, S., Spreux-Varoquaux, O., Olivares, R., Launay, J.M. & Puech, A.J. Monoamine oxidase activities in heavy smokers. Biol. Psychiatry 38, 756-761 (1995).
16. Berlin, I., Spreux-Varoquaux, O. & Launay, J.-M. Platelet monoamine oxidase activity is inversely associated with plasma cotinine concentration. Nicotine Tob. Res. 2, 243-246 (2000).
17. Gilbert, D.G. et al. Platelet monoamine oxidase B activity changes across 31 days of smoking abstinence. Nicotine Tob. Res. 5, 813-819 (2003).
18. Fowler, J.S. et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 379, 733-736 (1996).
19. Fowler, J.S. et al. Brain monoamine oxidase A inhibition by cigarette smokers. Proc. Natl. Acad. Sci. USA 93, 14065-14069 (1996).
20. Fowler, J.S., Logan, J., Wang, G.-J. & Volkow, N.D. Monoamine oxidase and cigarette smoking. Neurotoxicology 24, 75-82 (2003).
21. Herraiz, T. & Chaparro, C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem. Biophys. Res. Commun. 326, 378-386 (2005).
22. Hauptman, N. & Shih, J.C. 2-Napthylamine, a compound found in cigarette smoke, decreases both monoamine oxidase A and B catalytic activity. Life Sci. 68, 1231-1241 (2001).
23. Khalil, A.A., Steyn, S. & Castagnoli, N.J. Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem. Res. Toxicol. 13, 31-35 (2000).
24. Berlin, I. et al. Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction 97, 1347-1354 (2002).
25. George, T.P. Medication Treatments for Nicotine Dependence 1st edn. 327 pp (Taylor and Francis, Boca Raton, FL, 2006).